Our Pricing

Metformin vs Mounjaro Monthly Cost - UK Pricing Guide

Published on: June 03, 2026

Understanding the metformin vs Mounjaro monthly cost UK comparison is essential when choosing weight management treatment. At Cured Pharmacy, we provide transparent pricing with Mounjaro available from £124.99 per month, alongside expert clinical guidance to help you select the most suitable option. Both medications require assessment by a UK prescriber, but they differ significantly in mechanism, efficacy, and cost structure.

Monthly Cost Breakdown: Metformin vs Mounjaro in the UK

Metformin is typically available on NHS prescription for type 2 diabetes at standard prescription charges, currently £135.00 per item in England, though it's prescribed off-label for weight management in specific circumstances. Private prescriptions for metformin generally range between £135.00-£135.00 monthly depending on dose and pharmacy, making it one of the most affordable pharmacological options for metabolic support.

Mounjaro (tirzepatide) represents a premium treatment tier, priced at £124.99 per month at Cured Pharmacy for the starting dose. This reflects its status as a newer, dual-action GIP/GLP-1 receptor agonist with substantially greater weight loss efficacy demonstrated in clinical trials [1]. The monthly cost may increase with dose escalation, which your UK prescriber determines based on tolerance and clinical response.

When evaluating monthly expenditure, consider that metformin typically requires three-times-daily dosing and produces modest weight loss as a secondary effect, whilst Mounjaro offers once-weekly injection convenience with primary weight loss indications. The cost difference reflects not just the medication itself, but the clinical outcomes each treatment delivers.

How Metformin and Mounjaro Work Differently

Metformin functions primarily as an insulin sensitiser, reducing hepatic glucose production and improving peripheral glucose uptake. Its weight management effects are secondary, typically producing modest reductions through improved insulin sensitivity and mild appetite suppression. Clinical data shows metformin may support average weight loss of 2-3% body weight over six months when combined with lifestyle modifications [2].

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management. This dual mechanism activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing superior glycaemic control and substantial appetite reduction. In the SURMOUNT-1 trial, participants achieved average weight loss of 20.9% body weight at the 15mg dose over 72 weeks [1].

The pharmacological difference explains the cost disparity: metformin is a decades-old generic medication with modest weight effects, whilst Mounjaro represents cutting-edge incretin therapy specifically engineered for significant weight reduction. Your UK prescriber will assess which mechanism aligns with your clinical needs, metabolic profile, and weight management goals.

Mechanism of Action Comparison

Metformin's primary action occurs in the liver, where it activates AMP-activated protein kinase (AMPK), reducing glucose output and improving insulin signalling. Weight loss occurs indirectly through metabolic optimisation rather than direct appetite suppression. Patients typically notice gradual, modest changes over several months.

Tirzepatide's dual receptor activation creates synergistic effects on both glucose metabolism and satiety signalling. GLP-1 activation slows gastric emptying and reduces appetite centrally, whilst GIP activation enhances insulin secretion and may influence fat metabolism. This coordinated mechanism produces substantially greater weight reduction compared to single-pathway treatments [3].

Clinical Efficacy: What the Evidence Shows

Head-to-head trials directly comparing metformin and tirzepatide for weight management are limited, but individual trial data provides clear efficacy benchmarks. Metformin monotherapy typically produces 2-3% body weight reduction over six months in patients without diabetes, with effects plateauing thereafter [2]. It's most effective when initiated early in metabolic dysfunction and combined with structured lifestyle intervention.

Mounjaro demonstrates substantially greater efficacy across multiple trials. The SURMOUNT-1 study showed dose-dependent weight loss: 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg weekly doses over 72 weeks [1]. The SURMOUNT-3 trial further demonstrated that participants who achieved initial weight loss maintained reductions with continued tirzepatide therapy [4].

For patients requiring significant weight reduction—typically those with BMI over 30 or BMI over 27 with comorbidities—Mounjaro's clinical profile justifies the higher monthly cost through superior outcomes. Metformin remains valuable for metabolic support and modest weight management, particularly in patients with insulin resistance or prediabetes where its primary glucose-lowering effects provide additional benefit.

Who Should Consider Each Treatment Option

Metformin suits patients with early metabolic dysfunction, insulin resistance, or prediabetes who require modest weight support alongside glucose management. It's particularly appropriate for younger patients with PCOS-related weight gain, those seeking an affordable first-line option, or individuals who've achieved significant lifestyle changes but need pharmacological support to break through a plateau. Your UK prescriber may recommend metformin if you have contraindications to GLP-1 therapies or prefer oral medication.

Mounjaro is indicated for adults with BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea [1]. It's most suitable for patients requiring substantial weight reduction, those who haven't achieved adequate results with lifestyle modification alone, or individuals with previous GLP-1 experience seeking enhanced efficacy through dual-receptor activation.

Your clinical assessment at Cured Pharmacy evaluates your complete medical history, current medications, weight loss goals, and any contraindications. Our UK prescribers consider factors including previous treatment responses, injection tolerance, budget considerations, and long-term sustainability when recommending between these options.

Contraindications and Precautions

Metformin is contraindicated in patients with severe renal impairment (eGFR below 30 mL/min/1.73m²), acute metabolic acidosis, or conditions predisposing to lactic acidosis. Gastrointestinal side effects including diarrhoea, nausea, and abdominal discomfort occur commonly during initiation but typically resolve with continued use and dose titration.

Mounjaro carries contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and previous serious hypersensitivity to tirzepatide. Common side effects include nausea, diarrhoea, vomiting, and constipation, which are generally mild to moderate and diminish over time [1]. Your prescriber will review your complete medical history before recommending either treatment.

Cost-Effectiveness and Long-Term Value

When evaluating metformin vs Mounjaro monthly cost UK implications, consider cost-effectiveness beyond the monthly price tag. Metformin's lower cost makes it accessible for extended use, but modest efficacy means some patients require additional interventions or escalation to more effective treatments. The monthly expenditure is lower, but time to goal weight is substantially longer.

Mounjaro's higher monthly cost reflects superior efficacy that may shorten overall treatment duration. Patients achieving 20% body weight reduction within 72 weeks may reach clinical goals faster than with incremental approaches, potentially reducing total treatment costs over time. Additionally, substantial weight loss may reduce expenditure on comorbidity management including antihypertensives, lipid-lowering agents, and diabetes medications.

NICE guidance on obesity management emphasises that cost-effectiveness should account for quality-adjusted life years (QALYs) and comorbidity reduction, not just medication acquisition costs [5]. For patients with significant obesity-related health burdens, investing in highly effective treatment like Mounjaro may deliver greater long-term value despite higher monthly costs. Your UK prescriber can help evaluate which approach offers optimal value for your individual circumstances.

Getting Started at Cured Pharmacy

Beginning your weight management journey at Cured Pharmacy starts with our free online consultation, completed in under three minutes. Our UK-registered prescribers review your medical history, current medications, weight loss goals, and any relevant comorbidities to determine whether metformin, Mounjaro, or alternative treatments best suit your needs. All consultations are conducted by GPhC-registered clinicians adhering to MHRA prescribing guidelines.

If Mounjaro is deemed appropriate and you have no contraindications, your prescription is processed immediately with discreet delivery direct to your address. Our transparent pricing means you see the exact monthly cost before consultation—Mounjaro from £124.99 with no hidden fees or surprise charges. We dispense only genuine UK-licensed medications sourced through regulated supply chains.

Ongoing support includes medication guidance from our pharmacy team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), dosage adjustment consultations as you progress through titration schedules, and access to clinical advice throughout your treatment journey. Whether you're comparing initial options or seeking to optimise existing therapy, our team provides expert guidance grounded in current evidence and UK clinical standards.

What to Expect During Treatment

Metformin typically requires two to four weeks of gradual dose escalation to minimise gastrointestinal side effects, with most patients reaching therapeutic doses of 1500-2000mg daily. Weight changes emerge gradually over 8-12 weeks, with maximum effects typically seen by six months. Regular monitoring of renal function is recommended, particularly in patients over 65 or those with existing kidney concerns.

Mounjaro follows a structured titration schedule starting at 2.5mg weekly for four weeks, increasing to 5mg, then potentially to 7.5mg, 10mg, 12.5mg, or 15mg based on tolerance and response [1]. Most patients notice appetite reduction within the first week, with progressive weight loss accelerating after dose optimisation. Your UK prescriber schedules follow-up assessments to monitor progress, adjust dosing, and address any side effects.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Diabetes Prevention Program Research Group. (2012). Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care, 35(4), 731–737. https://doi.org/10.2337/dc11-1299 [accessed 13 August 2026]
3. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Aronne, L. J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Metformin and Mounjaro are prescription-only medications that must be prescribed following appropriate clinical evaluation. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, lifestyle modifications, and metabolic response. Always consult a qualified healthcare professional before starting any new medication or weight management programme.